GLP-1 Constipation: Causes, How Long It Lasts, and How to Get Relief

Why GLP-1 Medications Cause Constipation

GLP-1 receptor agonists slow the entire gastrointestinal tract, not just the stomach. Reduced motility through the small bowel and colon gives water more time to be absorbed from stool, and the result is harder, less frequent bowel movements. Three overlapping mechanisms drive this effect.

Delayed gastric emptying. GLP-1 receptors are expressed throughout the enteric nervous system. When semaglutide or tirzepatide activates these receptors, gastric emptying slows by roughly 20 to 35%, a finding confirmed by scintigraphy studies in healthy volunteers [1]. That delay cascades downstream, reducing the rate at which chyme enters the colon.

Reduced intestinal secretion. GLP-1 receptor activation suppresses mucosal secretion of water and electrolytes into the gut lumen. Less luminal fluid means drier, compacted stool and a longer transit time.

Central nervous system effects. GLP-1 receptors in the brainstem and hypothalamus modulate vagal tone. Reduced vagal drive decreases the frequency of colonic propulsive contractions, the "mass movements" that normally push stool toward the rectum several times per day.

In STEP-1 (Wilding et al., NEJM 2021, N=1,961), constipation was reported by 23.4% of participants on semaglutide 2.4 mg versus 11.1% on placebo, with most events rated mild to moderate [1]. In SURMOUNT-1 (Jastreboff et al., NEJM 2022, N=2,539), constipation occurred in 17% of patients on tirzepatide 15 mg versus approximately 6% on placebo [2]. Both trials define constipation by patient report, so the true physiological prevalence may be somewhat higher because mild cases often go unreported.

The Wegovy prescribing information lists constipation as a very common adverse reaction (occurring in >10% of subjects) and notes that it was among the GI events most frequently cited in dose-escalation periods [3]. The Zepbound label carries a comparable warning for tirzepatide [4].

How Long Does GLP-1 Constipation Last?

For most patients, constipation is worst during the first 4 to 8 weeks and during each dose step-up. It generally improves within 8 to 12 weeks of reaching a stable maintenance dose.

GLP-1 drugs are started at a low dose and titrated upward on a fixed schedule, typically every 4 weeks for semaglutide and every 4 weeks for tirzepatide. Each dose increase triggers a new wave of enteric slow-down. Patients who experience constipation at the 0.5 mg semaglutide starting dose often find it returns briefly when they advance to 1 mg, then 2 mg, and so on up to 2.4 mg. The good news: the gut adapts. A 2022 analysis of STEP-5 (N=304, 104-week treatment duration) showed that GI adverse events as a class declined substantially after week 20, even as patients remained on full-dose semaglutide [5]. Constipation specifically followed that pattern, with event rates dropping from roughly 8% in the first 20 weeks to under 3% in the final 40 weeks of the trial.

Patients with pre-existing slow-transit constipation or irritable bowel syndrome with constipation (IBS-C) may experience more prolonged symptoms. A clinical assessment before starting a GLP-1 agent is appropriate for anyone with a documented history of these conditions.

First-Line Management: Fiber and Hydration

Dietary fiber and fluid intake are the starting point for managing GLP-1-related constipation, and they often work without any medication.

The American College of Gastroenterology recommends 25 to 38 grams of fiber per day for adults with chronic constipation [6]. Most Americans consume only 10 to 15 grams daily, so the gap is significant. Soluble fiber (oats, psyllium husk, beans, apples) draws water into the stool and softens it. Insoluble fiber (whole wheat, vegetables, nuts) adds bulk. A psyllium supplement such as Metamucil, starting at 1 teaspoon (3.4 g) in 8 oz of water once daily and titrating to twice or three times daily, is a practical strategy for patients who cannot meet fiber targets through diet alone.

Hydration matters just as much. Because GLP-1 medications suppress appetite, patients often consume far fewer calories and, coincidentally, far less water-containing food. Aiming for at least 2 to 3 liters of total fluid per day (water, herbal tea, broth) reduces stool hardness independently of fiber intake.

Physical activity also accelerates colonic transit. Even 20 to 30 minutes of walking per day has been shown to reduce constipation severity scores versus sedentary controls [7]. For patients on GLP-1 therapy who are also enrolled in a lifestyle modification program, such as those in STEP-3 (Wadden et al., JAMA 2021, N=611), the combination of medication and structured exercise may actually partially offset constipation risk compared to medication alone [8].

Second-Line Management: Over-the-Counter Laxatives

When fiber and fluids fail after 5 to 7 days, osmotic and stool-softening laxatives are safe and appropriate.

Polyethylene glycol (PEG) 3350. Sold as MiraLAX and available generic, PEG 3350 at 17 g dissolved in 4 to 8 oz of fluid once daily is the preferred osmotic agent for most adults. It is non-habit-forming, tasteless, and has an excellent safety record in adults and children. A Cochrane review of osmotic laxatives found PEG consistently superior to lactulose in stool frequency and consistency [9].

Docusate sodium 100 mg twice daily. This stool softener reduces surface tension at the stool-water interface, allowing more water absorption by the stool. Evidence for docusate as monotherapy is weaker than for PEG, but it is useful in combination when the stool is particularly hard and dry.

Bisacodyl 5 to 10 mg at bedtime. A stimulant laxative for short-term rescue when a bowel movement has not occurred in 3 or more days. Use should be limited to 2 to 3 times per week to avoid laxative dependence.

What to avoid. Stimulant laxatives used daily, excessive magnesium citrate, and enemas without physician oversight are generally unnecessary for GLP-1-related constipation and may cause electrolyte disturbances in patients who are already eating less and drinking less than usual.

Managing Nausea Alongside Constipation

Nausea is the most common GLP-1 side effect overall, affecting 44.2% of semaglutide-treated participants in STEP-1 versus 16.2% on placebo [1]. Constipation and nausea often coexist because both stem from the same delayed-motility mechanism. Managing one without addressing the other leaves patients unnecessarily uncomfortable.

Several practical strategies reduce nausea without worsening constipation.

Eating smaller, more frequent meals (4 to 5 small meals rather than 2 to 3 large ones) reduces peak gastric distension, which is the primary nausea trigger with GLP-1 agents. Avoiding high-fat meals is equally important because fat is the strongest stimulus for GLP-1-mediated gastric-emptying delay.

Ginger has modest but real evidence behind it. A meta-analysis of 12 randomized controlled trials found ginger supplementation at 1 g per day reduced nausea scores by approximately 40% versus placebo across pregnancy, chemotherapy, and postoperative contexts [10]. While no semaglutide-specific nausea trial has tested ginger head-to-head, the mechanism (5-HT3 receptor modulation) is directly relevant to GLP-1-induced nausea. Patients can use ginger tea, crystallized ginger, or a 500 mg capsule twice daily.

For moderate to severe nausea that persists despite dietary adjustments, ondansetron 4 mg orally as needed (up to 3 times daily) is an off-label option that clinicians at HealthRX use after standard measures fail. The FDA-approved prescribing information for both Wegovy and Zepbound recommends dose reduction as the primary strategy when GI side effects are intolerable [3][4].

Sulfur Burps: Mechanism and Relief

Sulfur burps, described by patients as "rotten egg" or "eggy" belching, are a specific and underreported GLP-1 side effect that causes significant distress.

The mechanism is straightforward. When gastric emptying slows, food sits in the stomach for longer than usual. Sulfur-containing amino acids in protein foods (cysteine, methionine) undergo partial bacterial fermentation, producing hydrogen sulfide gas. That gas refluxes upward as foul-smelling belches.

Dietary modifications are the most effective intervention. Reducing intake of high-sulfur foods such as eggs, red meat, cruciferous vegetables (broccoli, cauliflower, Brussels sprouts), garlic, and onions can significantly reduce hydrogen sulfide production. These foods are not permanently off-limits; patients generally find that sulfur burps improve substantially after the first 8 to 12 weeks as their body adjusts to slower gastric emptying.

Simethicone 125 mg after meals reduces gas-related symptoms and may partially help with sulfur burps by accelerating gas coalescence and transit, though direct evidence for hydrogen sulfide specifically is limited to case reports. Eating slowly and avoiding carbonated beverages limits the amount of swallowed air that mixes with sulfur gas in the stomach.

The HealthRX clinical team recommends a practical four-step approach for patients reporting sulfur burps: (1) audit dietary sulfur intake for 3 days using a simple food diary; (2) eliminate the top two sulfur-containing foods for 2 weeks; (3) add simethicone 125 mg after each main meal; (4) if burps persist beyond week 12 at maintenance dose, consider a dose reduction discussion with the prescribing provider. Most patients who follow steps 1 through 3 report noticeable improvement within 7 to 14 days.

Gallbladder Risk: What the Data Show

GLP-1 receptor agonists are associated with a small but real increased risk of cholelithiasis (gallstones) and, less commonly, cholecystitis (gallbladder inflammation).

In STEP-1, cholelithiasis occurred in 1.6% of semaglutide-treated patients versus 0.7% on placebo, a statistically significant difference [1]. The SELECT cardiovascular outcomes trial (Lincoff et al., NEJM 2023, N=17,604) showed a similar signal: gallbladder-related adverse events were reported in 2.8% of semaglutide patients versus 2.3% on placebo over a median of 39.8 months [11]. In SURMOUNT-1, cholecystitis occurred in 0.6% of tirzepatide patients at the 15 mg dose [2].

The mechanism is well established. Rapid weight loss reduces bile acid pool cycling and increases biliary cholesterol saturation, a prerequisite for cholesterol gallstone formation. GLP-1 agonists may also reduce gallbladder contractility directly, as GLP-1 receptors are expressed on gallbladder smooth muscle. Reduced contraction means bile sits longer in the gallbladder, raising the risk of stone nucleation.

Patients with prior gallbladder disease, a family history of gallstones, or rapid weight loss of more than 1.5 to 2 kg per week face a higher baseline risk. The American Association for the Study of Liver Diseases recommends ursodeoxycholic acid (ursodiol) 600 mg daily for patients losing weight rapidly after bariatric surgery to prevent gallstone formation [12]. Some clinicians extend this logic to GLP-1-treated patients who are losing weight at the upper end of the observed range, though no randomized trial has yet confirmed this benefit in the GLP-1 population specifically.

Symptoms warranting urgent evaluation include right upper quadrant or epigastric pain (especially postprandial), fever, jaundice, or dark urine. These should not be attributed to routine GLP-1 GI side effects without imaging.

GLP-1 Side Effects Overview: The Full Picture

Understanding constipation in context requires knowing the full GI side effect profile of these medications.

In STEP-1, the four most common adverse events on semaglutide 2.4 mg were nausea (44.2%), diarrhea (31.5%), vomiting (24.8%), and constipation (23.4%) [1]. In SURMOUNT-1 on tirzepatide 15 mg, the four most common were nausea (39%), diarrhea (23%), constipation (17%), and vomiting (13%) [2]. Discontinuation due to GI adverse events occurred in approximately 7% of semaglutide patients in STEP-1 and a similar proportion in SURMOUNT-1.

Several observations help patients understand what to expect.

First, nausea and diarrhea tend to peak early (weeks 1 to 4) while constipation builds more gradually and often persists longer. A patient who tolerates the first few weeks without constipation is not necessarily protected from it once they reach higher doses.

Second, GI events cluster around dose increases. STEP-8 (Rubino et al., JAMA 2022, N=338), comparing semaglutide 2.4 mg to liraglutide 3.0 mg, found that semaglutide produced greater weight loss (15.8% vs. 6.4%) but also somewhat higher rates of nausea and vomiting during escalation [13]. Liraglutide showed a modestly lower GI burden during titration, a relevant consideration for patients who have discontinued semaglutide or tirzepatide specifically due to GI intolerance.

Third, slower titration helps. Both the Wegovy and Zepbound labels allow for extended dose-escalation schedules in patients who experience GI intolerance [3][4]. Clinically, spending 8 weeks at a given dose rather than 4 weeks before advancing reduces the frequency and severity of GI events in most patients.

As the Endocrine Society's 2023 pharmacotherapy of obesity guideline states: "GLP-1 receptor agonist therapy should be initiated at the lowest available dose and titrated slowly, prioritizing tolerability over speed of titration, particularly in patients with preexisting gastrointestinal conditions." [14]

When to Call Your Doctor

Most GLP-1-related constipation is manageable at home. A handful of presentations require prompt medical attention.

Call your prescribing provider or seek same-day care if you have not had a bowel movement in 5 or more days despite laxative use, experience significant abdominal distension or cramping, notice blood in your stool, or develop right upper quadrant pain that could suggest gallbladder involvement.

Go to an emergency department if you develop severe abdominal pain that is constant and radiating to the back (possible pancreatitis), fever above 38.5°C with abdominal pain, jaundice, or signs of significant dehydration such as dizziness on standing, heart rate above 110 beats per minute, or urine that is very dark.

Pancreatitis is rare but real. In a pooled analysis of GLP-1 trials, the incidence of acute pancreatitis was approximately 0.1 to 0.3% annually in treated patients versus a background rate of roughly 0.05 to 0.1% in similar untreated populations [15]. Persistent mid-epigastric pain is not a GI side effect to self-manage.

Dose Management: When Slowing Down Makes Sense

Reducing the dose or pausing the titration schedule is an underused and effective tool for managing persistent constipation and other GI side effects.

Both the Wegovy and Zepbound labels explicitly permit staying at a lower dose for an additional 4 weeks (or longer) if the current dose is not tolerated [3][4]. Clinical data from SURMOUNT-2 (Jastreboff et al., Lancet 2023, N=938) show that tirzepatide at 10 mg produced mean weight loss of 13.4% at 72 weeks, compared to 15.7% at 15 mg [16]. For patients with severe GI side effects, the modest difference in weight loss between the maximum tolerated dose and the next lower dose is generally a reasonable trade for meaningful improvement in quality of life.

The AACE/ACE obesity clinical practice guidelines note that patient adherence to pharmacotherapy is the most important predictor of long-term weight maintenance, and that side effect management is central to sustaining adherence [17]. A patient who reduces the dose by one step and remains on therapy for 2 years will achieve better outcomes than one who pushes to the highest dose and discontinues at 6 months.